23 Jun 26
By Judi Proctor
tranScrip is delighted to have contributed to the publication of the first-in-human clinical study of SDC-1801, an oral TYK2/JAK1 inhibitor being developed by Sareum Holdings, in the British Journal of Clinical Pharmacology, co-authored by tranScrip experts Chris Brearley and Judi Proctor, with John Reader and Sam Francis.
The publication, titled First-in-human, phase I, randomised, safety, pharmacokinetic, food-effect, and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC-1801, reports that SDC-1801 was well tolerated across doses with a range of 5 to 150 mg, with a pharmacokinetic profile consistent with once-daily oral dosing and evidence of target engagement for both TYK2 and JAK1,
This publication represents an important milestone for Sareum Holdings and the wider study team, providing a comprehensive clinical and pharmacological characterisation of SDC-1801 supporting the continued development of SDC-1801 for autoimmune diseases.
tranScrip is proud to have contributed to the communication and dissemination of these important clinical findings, helping to support the sharing of scientific evidence with the wider research community.
Read Sareum’s announcement
https://otp.tools.investis.com/clients/uk/sareum_holdings_plc/rns/regulatory-story.aspx?cid=2841&newsid=2068517
Read the open access article
http://doi.org/10.1002/bcp.70642
Contact Us
At tranScrip, we support clients from early clinical development to market and beyond, helping communicate complex science with clarity, accuracy and impact. Contact us to find out how we can support your development programmes: Contact tranScrip | A Specialist Pharmaceutical Consultancy
Get in touch to see how our senior cross-functional experts can help you reduce risk, protect value, and move forward with confidence.